Advertisements
Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category


Retweets, Likes of Tweets by @AVIVA1950 @pharma_BI on May 8, 2018 for 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott,  Cambridge

@USAIC #USAIC2018

Curator: Aviva Lev- Ari, PhD, RN

 

Re-Tweets of MY TWEETS: via

@pharma_BI

@AVIVA1950

for 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge

@USAIC

#USAIC2018

 

Stephen J Williams Retweeted your Tweet

 

Aviva Lev-Ari @AVIVA1950

Dr. David Goldstein, Director, Institute for Genomic Medicine, Columbia University Medical Center Clinical Trials in AD are very expensive collection of Data of AD populations for subgroups of Patients: Epilepsy vs AD Heterogeneity of AD @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

SYNOPSIS @USAIC #USAIC2018 by @pharma_BI @AVIVA1950 for 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge https://pharmaceuticalintelligence.com/2018/01/18/12th-annual-us-india-biopharma-healthcare-summit-may-8-2018-marriott-cambridge/ … via @Pharma_BI

 

Aviva Lev-Ari @AVIVA1950

Dr. Meeta Chatterjee, Head, Business Strategy & Operations, Business Development & Licensing, Merck Research Labs Biomarkers as surugate for Outcomes reduce cost of drug development very expensive @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

@SteliosPapadopoulos @Biogen Investors in Public Companies 80s Biotech @biogen @Genzyme @Amgen @Genetech in 90s @MedicinalChemistry Disappointment 2000-2010, Excitement 2015 on investment is generously @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

Academic Young entrepreneurs How the split of the rewards determined between the Academic institutions and the Investor? @AnsbertGadicke in China and in The US that definition of rewards is very different. @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

BioParma Innovation + @AffordablePrice Measurable #MedicalVALUE Drivers of Positive return on R&D: #Payers, #Genomics, #smartmoney, #sophisticatedconsumers of messy #data identify UNDIAGNOZED Patients @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

Academic Young entrepreneurs How the split of the rewards determined between the Academic institutions and the Investor? #AnsbertGadicke in CHina and in The US that definition of rewards is very different. @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

@BruceChabner @MGH@HMS @DanaFarber they CREATED the Diagnostics Industry via Genomics pioneering testing and linking to therapy Most of the World does not have ACCESS to #Diagnostics for #PatientSelection @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

#PhilipRowlands, Head of the Oncology Therapeutic Area Unit, @Takeda Pharmaceuticals Oncology got MOST investment by Pharma assays challenge of Resistence, how prioritization of combination therapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Aviva Lev-Ari @AVIVA1950

Panel on Investment: @AnsbertGadicke, Founder & Managing Director @MPM Capital @SteliosPapadopoulos, Chairman @Biogen @TsutomuUne, Senior Corporate Advisor, @GCACorporation Moderator: @WilliamChin, Professor of Medicine, Emeritus @HMS @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Database Integration Retweeted your Tweet

Aviva Lev-Ari @AVIVA1950

@ShahramEbadollahi #IBM @Watson #blockchain #AI is foundational @ColinHill, Chairman & CEO, @GNSHealthcare believes in digitization in Healthcare #BigData used for #repurposing #drugdevelopment and new #drugcombinations development @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Albert Boxler and Logan Stewart followed you

Jerome Gels liked your Tweet

Aviva Lev-Ari @AVIVA1950

BioParma Innovation + @AffordablePrice Measurable #MedicalVALUE Drivers of Positive return on R&D: #Payers, #Genomics, #smartmoney, #sophisticatedconsumers of messy #data identify UNDIAGNOZED Patients @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Eliances Community liked your Tweet

@SteliosPapadopoulos @Biogen Investors in Public Companies 80s Biotech @biogen @Genzyme @Amgen @Genetech in 90s @MedicianlChemistry Disappointment 2000-2010, Excitement 2015 on investment is generously @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Zos liked your reply

Aviva Lev-Ari @AVIVA1950

@StevenPaul CEO @VoyagerTherapeutics #Bipolar #Schizophrenia much development of techniques and methodologies but these diseases are not well known, yet new cycle of development on its way @USAIC #USAIC2018 @pharma_BI @AVIVA1950

Cris De Luca liked your Tweet

Aviva Lev-Ari @AVIVA1950

@MathaiMammen @JnJ Emphasize Disease vs Organizational assignment of science space is crucial hiring people with conviction @MichaelEhlers @Biogen BEST people for Science bench @AndrewPlump @Takeda all efforts on PARTNERSHIPS and culture @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Genomics Edtech Retweeted your Tweet

Aviva Lev-Ari @AVIVA1950

BioParma Innovation + @AffordablePrice Measurable #MedicalVALUE Drivers of Positive return on R&D: #Payers, #Genomics, #smartmoney, #sophisticatedconsumers of messy #data identify UNDIAGNOZED Patients @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

C The Crypto FoxBharat Ghankutkar and GNS Healthcare liked your Tweet

Aviva Lev-Ari @AVIVA1950

@ShahramEbadollahi #IBM @Watson #blockchain #AI is foundational @ColinHill, Chairman & CEO, @GNSHealthcare believes in digitization in Healthcare #BigData used for #repurposing #drugdevelopment and new #drugcombinations development @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Cash For Your Warhol liked your Tweet

Aviva Lev-Ari @AVIVA1950

#VijayChandru, Chairman, @StrandLifeSciences Cost compression Data scientists cooperation on Health IT US and India model @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Crypto Goddess 🙂 liked your Tweet

Aviva Lev-Ari @AVIVA1950

#Blockchain platform decision medicine drugs, #AI leverage data already existing find new dedication from data collected in the past @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Sarah Morgan liked your reply

Aviva Lev-Ari @AVIVA1950

@JonathanEpstein @UPenn collaboration with 200 Novartis employees on site at the Medical School Clinical Trial and Manufacturing Cell-based therapies OUTSTANDING Clinicians kept the patient alive during the drug development immunetherapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Nate Agapi and Justin Farrell followed you

 

Rubeena Qurashi liked your Tweet

Aviva Lev-Ari @AVIVA1950

Discovery to Commercialization – Data is Fragmented across institutions Diabetes Patients had higher risk for CVD in comparison to Obese Patient non-Diabetes – that data to confirm and monitor was not integrated. @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Cash For Your Warhol liked your Tweet

Aviva Lev-Ari @AVIVA1950

#NeuroDiseases Panelists: @AlfredSandrock @Biogen @DavidGoldstein @Columbia @MaurizioFava @HMS @MeetaChatterjee @Merck @StevenPaul @Voyager @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Georgia Mitsi and USAIC Retweeted your reply

Aviva Lev-Ari @AVIVA1950

@JonathanEpstein @UPenn collaboration with 200 Novartis employees on site at the Medical School Clinical Trial and Manufacturing Cell-based therapies OUTSTANDING Clinicians kept the patient alive during the drug development immunetherapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Georgia Mitsi liked your reply

Aviva Lev-Ari @AVIVA1950

@JonathanEpstein @UPenn collaboration with 200 Novartis employees on site at the Medical School Clinical Trial and Manufacturing Cell-based therapies OUTSTANDING Clinicians kept the patient alive during the drug development immunetherapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

 

MY TWEETS: via

@pharma_BI

@AVIVA1950

at for 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge

@USAIC

#USAIC201

2 replies 32 retweets 49 likes

 

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

SYNOPSIS @USAIC #USAIC2018 by @pharma_BI @AVIVA1950 for 12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge https://pharmaceuticalintelligence.com/2018/01/18/12th-annual-us-india-biopharma-healthcare-summit-may-8-2018-marriott-cambridge/ … via @Pharma_BI

 

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@AndrewPlump Chief Medical and Scientific Officer @Takeda Role of #AcademicInstitutions in Innovation and R&D?

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@VijayChandru, Chairman, @StrandLifeSciences Cost compression Data scientists cooperation on Health IT US and India model @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@ShahramEbadollahi @IBMWatson Access of Patient data, clinical Trial data, medical record data Tested on a Bitcoin platform using encryption as a Trusted distributed data architecture system @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@ShahramEbadollahi @IBMWatson #AI #Bitcoin is a platform for integration of all the records for Watson platform transaction – establish TRUST based on the cryptography of the system consent to share data FDA and CDC as Partner to TEST data @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

Technology Platforms @ChrisBenko, Co-Founder & CEO @KoneksaHealth @ColinHill CEO @GNSHealthcare @PeterMueller, Chairman, @BioXcelTherapeutics @ShahramEbadollahi @IBM Watson Health Group, IBM @VijayChandru, Chairman @StrandLifeSciences @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@SusanHockfield ex-President @MIT Thesis is a source of ideas @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@GeorgeDaley Dean @HMS PhD Program Faculties spend Sabbaticals in Industry BIOLOGY IS ADVANCING FAST NEW PROGRAMS FOR HTERAPIES @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

Like

 

 

View Tweet activity

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@SusanHockfield ex-President @MIT the INTELLIGENT WEST #AI # Radiology interpretation @ReginaBarzilay revising curriculum to reinvent the FIELD basket of problems industry people on Campus searching @MIT Basket of experiment & ideas @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@GeorgeDaley Dean @HMS Tools penetration systems going back and forth between models Interdisciplinary institutes, @Harvard Centers for research Projects do not get advanced enough to interest VCs 100 faculties mroject not advanced enough @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@SusanHockfield ex-President @MIT Foundations MIT faculties go back and forth to Industry Research in Educ Institution, purpose of Univ different that Top-DOwn Org producing @MIT #engineering and #BiologicalSciences are placed together @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

@GeorgeDaley Dean @HMS Science happens faster, ecosystem In 15 yrs different system rethink new ways 35 years of incubation accelerate process invest in regulatory change the Game to eb cheaper better faster invest in new Initiative @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

Fireside Chat: @GeorgeDaley Dean @HMS @SusanHockfield President Emerita & Professor of Neuroscience @MIT Moderator: @AndrewPlump Chief Medical and Scientific Officer @Takeda @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195019h19 hours ago

More

Academic Young entrepreneurs How the split of the rewards determined between the Academic institutions and the Investor? @AnsbertGadicke in CHina and in The US that definition of rewards is very different. @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@AnsbertGadicke, Founder & Managing Director, MPM Capital Invest in combinations therapy in one vial several times cheaper than each agent alone @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@SteliosPapadopoulos, Chairman @Biogen Studies on #Prevention – CVD Endpoint right drug to get to endpoint by clinical trials #Vaccines: validate science that it can be done @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@WilliamChin, Professor of Medicine, Emeritus, Harvard Medical School Notion A1C took decades to develop @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@TsutomuUne, Senior Corporate Advisor @GCA Corporation Need to care for ELderly population should direct the investment – we started with therapy then prevention @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@AnsbertGadicke, Founder & Managing Director @MPM Capital Academic founders of start ups – innovations from Academia @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@AnsbertGadicke, Founder & Managing Director @MPMCapital Investment of private funds $50Million in a start up on average stay away from Capital market @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@SteliosPapadopoulos, Chairman @Biogen New compounds is the name of the game for pipeline of drugs @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

 

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@TsutomuUne, Senior Corporate Advisor, @GCACorporation invest in buying the opportunity to participate @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@AnsbertGadicke @MPMCapital New Directions: Own money for IMPACT module invest in young investigators investment in Underdeveloped countries to offer access to drugs @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@SteliosPapadopoulos @Biogen Investors in Public Companies 80s Biotech @biogen @Genzyme @Amgen @Genetech in 90s @MedicianlChemistry Disappointment 2000-2010, Excitement 2015 on investment is generously @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

Panel on Investment: @AnsbertGadicke, Founder & Managing Director @MPM Capital @SteliosPapadopoulos, Chairman @Biogen @TsutomuUne, Senior Corporate Advisor, @GCACorporation Moderator: @WilliamChin, Professor of Medicine, Emeritus @HMS @USAIC #USAIC2018 @pharma_BI @AVIVA1950

Translate Tweet

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@VictoriaRichon, President & CEO @Ribon Therapeutics @KurtStoeckli @Glen Pharmaceuticals – EARLY detection continues to be the calprit of Therapy Outcome @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@VictoriaRichon, President & CEO, @Ribon Therapeutics Biomarker development for use in assignment of Patients to Clinical Trials @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@BruceChabner @MGH@HMS @DanaFarber they CREATED the Diagnostics Industry via Genomics pioneering testing and linking to therapy Most of the World does not have ACCESS to #Diagnostics for #PatientSelection @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

Reimbursement for Diagnostics @PhilipRowlands @Takeda Oncology is very competitive next generation is combination therapy – which one to own @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@RakeshJain @MGH @HMS Biomarkers needs for the micro-environment of the Tumors @KurtStoeckli #PrecisionTherapy will be key for cost efficiencies @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@BruceChabner @MGH @HMS – DRUG-Based Biomarkers – circulating DNA, Exosomes moving directly to Clinical Trials @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@PhilipRowlands, Head of the Oncology Therapeutic Area Unit, @Takeda Pharmaceuticals Oncology got MOST investment by Pharma assays challenge of Resistence, how prioritization of combination therapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@RakeshJain, #TumorBiology, @MGH Cancer Center @HMS Immuno supression caused by Hypoxia, improve oxigenation buy prescription of antihypertension drugs, stinulate the innume system checkpoint blockers @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

#Oncology Panelists: Moderator: @RajuKucherlapati @HMS @BruceChabner @MGH @HMS @KurtStoeckli @Glenmark @PhilipRowlands @Takeda @VictoriaRichon @RibonTherapeutics @RakeshJain @MGH @HMS @USAIC #USAIC2018 @pharma_BI @AVIVA1950

Translate Tweet

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@MathaiMammen @JnJ Emphasize Disease vs Organizational assignment of science space is crucial hiring people with conviction @MichaelEhlers @Biogen BEST people for Science bench @AndrewPlump @Takeda all efforts on PARTNERSHIPS and culture @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@MichaelEhlers, Head of Research & Development, Biogen moved from Pfizer to Biogen HUMAN BIOLOGY across the board scientific clinical judgement scientists that scrutinize data and are skeptical are reluctant to be Sales @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

@AndrewPlump, Chief Medical and Scientific Officer @Takeda Pharmaceuticals out of 12 drugs introduced in decade 4 got to market all were acquisitions transformation 2013 restructuring lab updates new pipeline – stabilize stage @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

Drug Discovery: @AndrewPlump, Chief Medical and Scientific Officer, @Takeda @MathaiMammen, Global Head of R&D, @Janssen Pharmaceutical- JnJ @MichaelEhlers, Head of Research & Development @Biogen Moderator: @Martin Mackay CEO @Rallybio @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195020h20 hours ago

More

BioParma Innovation + @AffordablePrice Measurable #MedicalVALUE Drivers of Positive return on R&D: #Payers, #Genomics, #smartmoney, #sophisticatedconsumers of messy #data identify UNDIAGNOZED Patients @USAIC #USAIC2018 @pharma_BI @AVIVA1950

0 replies 2 retweets1 like

  1. Aviva Lev-Ari‏ @AVIVA195021h21 hours ago

More

BioPharma: An Extraordinary BioPharma Disruption @AjayDhankhar, Senior Partner, @McKinsey @SastryChilukuri @McKinsey Big-4 Disruptions: #Aging #Urbanization #Globalization #TechnoAcceleration: #IT #Buildingblocks #Robotics #NewEnergy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

Translate Tweet

  1. Aviva Lev-Ari‏ @AVIVA195021h21 hours ago

More

@ShahramEbadollahi #IBM @Watson #blockchain #AI is foundational @ColinHill, Chairman & CEO, @GNSHealthcare believes in digitization in Healthcare #BigData used for #repurposing #drugdevelopment and new #drugcombinations development @USAIC #USAIC2018 @pharma_BI @AVIVA1950

0 replies1 retweet3 likes

  1. Aviva Lev-Ari‏ @AVIVA195022h22 hours ago

More

#Blockchain platform decision medicine drugs, #AI leverage data already existing find new dedication from data collected in the past @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195022h22 hours ago

More

#VijayChandru, Chairman, @StrandLifeSciences Cost compression Data scientists cooperation on Health IT US and India model @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195022h22 hours ago

More

#ShahramEbadollahi @IBMWatson Access of Patient data, clinical Trial data, medical record data Tested on a Bitcoin platform using encryption as a Trusted distributed data architecture system @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195022h22 hours ago

More

#ShahramEbadollahi @IBMWatson #AI #Bitcoin is a platform for integration of all the records for Watson platform transaction – establish TRUST based on the cryptography of the system consent to share data FDA and CDC as Partner to TEST data @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195022h22 hours ago

More

Technology Platforms #ChrisBenko, Co-Founder & CEO @KoneksaHealth #ColinHill CEO @GNSHealthcare #PeterMueller, Chairman, @BioXcelTherapeutics #ShahramEbadollahi @IBM Watson Health Group, IBM #VijayChandru, Chairman @StrandLifeSciences @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

Academic Young entrepreneurs How the split of the rewards determined between the Academic institutions and the Investor? #AnsbertGadicke in CHina and in The US that definition of rewards is very different. @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#SteliosPapadopoulos focus on DISTRUCTIVE treatment price control, regulation will impact investment @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#AnsbertGadicke, Founder & Managing Director, MPM Capital Invest in combinations therapy in one vial several times cheaper than each agent alone @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#SteliosPapadopoulos, Chairman @Biogen Studies on #Prevention – CVD Endpoint right drug to get to endpoint by clinical trials #Vaccines: validate science that it can be done @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#William Chin, Professor of Medicine, Emeritus, Harvard Medical School Notion A1C took decades to develop @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#TsutomuUne, Senior Corporate Advisor @GCA Corporation Need to care for ELderly population should direct the investment – we started with therapy then prevention @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#AnsbertGadicke, Founder & Managing Director @MPM Capital Academic founders of start ups – innovations from Academia @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#AnsbertGadicke, Founder & Managing Director @MPMCapital Investment of private funds $50Million in a start up on average stay away from Capital market @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#SteliosPapadopoulos, Chairman @Biogen New compounds is the name of the game for pipeline of drugs @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#TsutomuUne, Senior Corporate Advisor, @GCACorporation invest in buying the opportunity to participate @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#AnsbertGadicke @MPMCapital New DIrections: Own money for IMPACT module invest in young investigators investment in Underdeveloped countries to offer access to drugs @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195023h23 hours ago

More

#SteliosPapadopoulos @Biogen Investors in Public Companies 80s Biotech @biogen @Genzyme @Amgen @Genetech in 90s @MedicianlChemistry Disappointment 2000-2010, Excitement 2015 on investment is generousely @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

Panel on Investment: @AnsbertGadicke, Founder & Managing Director @MPM Capital #SteliosPapadopoulos, Chairman @Biogen @TsutomuUne, Senior Corporate Advisor, @GCACorporation Moderator: @WilliamChin, Professor of Medicine, Emeritus @HMS @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

@AndrewPlump, Chief Medical & Scientific Officer, @Takeda Pharmaceuticals In the Past Cancer was a death sentence NOT any more, we see therapy and cure in Oncology @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

#VictoriaRichon, President & CEO @Ribon Therapeutics #KurtStoeckli @Glen Pharmaceuticals – EARLY detection continues to be the calprit of Therapy Outcome @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

@RakeshJain, @MGH @HMS IF 85% of blood vessels in tumor are collapsed (hypoxia) how do you deliver drugs to the tumor?? @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

#Diagnostics is not a viable model for #Investors unless the reimbursement will change the process for diagnostics approval is like of drugs @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

#VictoriaRichon, President & CEO, @Ribon Therapeutics Biomarker development for use in assignment of Patients to Clinical Trials @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

#BruceChabner @MGH@HMS @DanaFarber they CREATED the Diagnostics Industry via Genomics pioneering testing and linking to therapy Most of the World does not have ACCESS to #diagnostics #Diagnostics for #PatientSelection @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

Reimbursement for Diagnostics #PhilipRowlands @Takeda Oncology is very competitive next generation is combination therapy – which one to own @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA195024h24 hours ago

More

#RakeshJain @MGH @HMS Biomarkers needs for the micro-environment of the Tumors #KurtStoeckli #PrecisionTherapy willl be key for cost efficiencies @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Dr. Kurt Stoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals – cost effectiveness by clinical trial design and biomarkers @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

#BruceChabner @MGH @HMS – DRUG-Based Biomarkers – circulating DNA, Exosomes moving directly to Clinical Trials @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

#PhilipRowlands, Head of the Oncology Therapeutic Area Unit, @Takeda Pharmaceuticals Oncology got MOST investment by Pharma assays challenge of Resistence, how prioritization of combination therapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@KurtStoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals Translational Experiment on going origin of the cells, microenvironment, immuno science models @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@VictoriaRichon, President & CEO @RibonTherapeutics DO we have the bIomarkers, do we ahve the right Trial, How to bring new therapies – agree Biomarkers are kEY @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Dr. Kurt Stoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals Testing the right combination therapy is critical @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Dr. Bruce Chabner, Director of Clinical Research, Mass General Hospital Cancer Center/Harvard Medical School told historic milestory in Oncology Therapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

#RakeshJain, #TumorBiology, @MGH Cancer Center @HMS Immuno supression caused by Hypoxia, improve oxigenation buy prescription of antihypertension drugs, stinulate the innume system checkpoint blockers @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

#Oncology Panelists: Moderator: #RajuKucherlapati @HMS #BruceChabner @MGH @HMS #KurtStoeckli @Glenmark #PhilipRowlands @Takeda #VictoriaRichon @RibonTherapeutics #RakeshJain @MGH @HMS @USAIC #USAIC2018 @pharma_BI @AVIVA1950

Translate Tweet

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@AlfredSandrock #CMO @Biogen Sensors better than neuro-cognitive testing and assessment of cognition @MaurizioFava @HMS The ALL OF US One Million Volunteer is very promising for research @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@DavidGoldstein, Director, Institute for Genomic Medicine, @Columbia University Medical Center Accelerate getting Knowledge of the disease, CF biology was known in AD combination of Amyloid in MRI Imaging and Genomics in combination @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@MaurizioFava @HMS Leverage Big Data very important in Clinical Trial Design, Biomarkers Using #ML on Data we are close best minds are applied to #AI Universities must become user-friendly to Industry for Clinical Trials @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@StevenPaul @VoyagerTherapeutics SLOWING the disease by 6 years save 50% of the dying from disease @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Moderator: @SteveUden, Co-Founder, @Rallybio Identify Early disease, @StevenPaul @VoyagerTherapeutics Biomarkers: if Amyloid at age 40 – progression to AD predicted, TAU predicts progression of AD @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Dr. David Goldstein, Director, Institute for Genomic Medicine, Columbia University Medical Center Clinical Trials in AD are very expensive collection of Data of AD populations for subgroups of Patients: Epilepsy vs AD Heterogeneity of AD @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Dr. Meeta Chatterjee, Head, Business Strategy & Operations, Business Development & Licensing, Merck Research Labs Biomarkers as surugate for Outcomes reduce cost of drug development very expensive @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@StevenPaul, President and Chief Executive Officer, Voyager Therapeutics CNS is not to be compare with antiCHolesterol DIsease, Ameloid is necessary not sufficient @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@MeetaChatterjee, Head, Business Strategy & Operations, Business Development & Licensing, @Merck In ImmunoOncology great success BUT in Dimentia and Alzheimer’s Disease NO success to compare @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@StevenPaul CEO @VoyagerTherapeutics #Bipolar #Schizophrenia much development of techniques and methodologies but these diseases are not well known, yet new cycle of development on its way @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@DavidGoldstein #GenomicMedicine @Columbia CNS diseases: ALS, Epilepsy NOT only and NOT primarily Genomics Focus on Disease but pathways, proteins @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Early Clinical Trials in #MultitpleSclerosis Breakthrough is using MRI for disease progression prediction @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

#NeuroDiseases Panelists: @AlfredSandrock @Biogen @DavidGoldstein @Columbia @MaurizioFava @HMS @MeetaChatterjee @Merck @StevenPaul @Voyager @USAIC #USAIC2018 @pharma_BI @AVIVA1950

Translate Tweet

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@JonathanEpstein Students are in need for internships with Industry and develop entrepreneurships @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

DIscovery to Commercialization – Data is Fragmented across institutions Diabetes Patients had higher risk for CVD in comparison to Obese Patient non-Diabetes – that data to confirm and monitor was not integrated. @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@ChasBountra @Oxford Accessing in the UK across all Academia opening resources: Goventment funds, Takeda helps in resources needed for integration of sources WHile in Academia Access across institutions is easier @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

In India explosion Hospitals adding Bioinformatics and Big Data Analytics, Databases on Infectious Diseases. Data Mining Pfizer is surveying disease data @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@ChasBountra Talking on MPACT, drug discovery the role of Academia is NOT ro replicate the excellence existing in Pharma, in Academia basic sciencec innovations to lead @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Partnership with academia to enrich the early pipeline with new drugs Transformation on matters of science no internal expertise exist @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@JonathanEpstein @UPenn collaboration with 200 Novartis employees on site at the Medical School Clinical Trial and Manufacturing Cell-based therapies OUTSTANDING Clinicians kept the patient alive during the drug development immunetherapy @USAIC #USAIC2018 @pharma_BI @AVIVA1950

0 replies 2 retweets 2 likes

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@SridaranNatesan major role played by New Prime Minister @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

In India major shift from publications in Journals to funding start ups, India Industry became bold, interaction with academia outside of India Sweden, Stanford, Boston – @JoslinClinic – Formulation Vaccine India Tech Transfer was a problem @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

@JonathanEpstein #CSO @UPenn Success of the Process wish to see results in our Life time IMPACT of innovations @USAIC #USAIC2018 @pharma_BI @AVIVA1950

 

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@JimGlasheen @UMMS Transfer Office has challenges of responsiveness to Faculty @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@NirmalKumarGanguly, President, @ApolloHospitals promising relationships with Academia changing mind set different organizational culture @USAIC #USAIC2018 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@ChasBountra, Chief Scientist, Structural #Genomics Consortium @Oxford discover NOVEL #reagents given to #Academia and #Pharma @USAIC #USAIC18 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

Industry-Academic Research Partnerships Moderator: @JuanHarrison @Takeda #Industry #BigPharma #Academia STORIES @ChasBountra @Oxford @JimGlasheen @UMass @JonathanEpstein @UPenn @NirmalKumarGanguly @ApolloHospitals @SridaranNatesan @Sanofi @USAIC #USAIC18 @pharma_BI @AVIVA1950

  1. Aviva Lev-Ari‏ @AVIVA1950May 8

More

@AndrewPlump, Chief Medical & Scientific Officer, @Takeda #Pharmaceuticals Government Challenges in India active is providing access and affordable #HealthCare @USAIC #USAIC18 @pharma_BI @AVIVA1950

Aviva Lev-Ari‏ @AVIVA1950 May 7

More

12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge @USAIC #USAIC18 @pharma_BI @AVIVA1950 https://pharmaceuticalintelligence.com/2018/01/18/12th-annual-us-india-biopharma-healthcare-summit-may-8-2018-marriott-cambridge/ … via @Pharma_BI

Advertisements

Read Full Post »


12th Annual US-India BioPharma & Healthcare Summit, May 8, 2018, Marriott Cambridge

http://usaindiachamber.org/speaker.php

@USAIC

#USAIC2018

 

Announcement

Aviva Lev-Ari, PhD, RN,

Founder and Director of LPBI Group will be in attendance covering the event in REAL TIME

@pharma_BI

@AVIVA1950

 

All TWEETS from LPBI’s Twitter.com handles at

@USAIC

#USAIC2018

by

@pharma_BI

@AVIVA1950

BioPharma & Healthcare Summit – May 8, 2018

Chair and Emcee – Dr. Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals

Time Topic
8-45 AM – 9-10 AM Registration and Networking
9-10 AM – 9-25 AM Welcome address: Karun Rishi, President, USA-India Chamber of Commerce (USAIC)

Opening comments: Dr Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals

9-25 AM – 10-15 AM Panel Discussion: Industry-Academic Research Partnerships

Panelists:

  • Dr. Chas Bountra, Chief Scientist, Structural Genomics Consortium Oxford, University of Oxford
  • Dr. Jim Glasheen, Executive Vice Chancellor, University of Massachusetts Medical School
  • Dr. Jonathan Epstein, Executive Vice Dean & Chief Scientific Officer, Perelman School of Medicine, University of Pennsylvania
  • Dr. Nirmal Kumar Ganguly, President, Apollo Hospitals Educational & Research Foundation
  • Dr. Sridaran Natesan, Head – Strategic Initiatives & Scientific Relations, R&D, Sanofi North America

Moderator:
Juan Harrison, Vice President, Head of Strategic Academic Alliances, Takeda Pharmaceuticals

10-15 AM – 11-05 AM Panel DiscussionNeuro Diseases                                                                                                          

Panelists:

  • Dr. Alfred Sandrock, Executive Vice President & Chief Medical Officer, Biogen
  • Dr. David Goldstein, Director, Institute for Genomic Medicine, Columbia University Medical Center
  • Dr. Maurizio Fava, Associate Dean, Clinical & Translational Research, Harvard Medical School
  • Dr. Meeta Chatterjee, Head, Business Strategy & Operations, Business Development & Licensing, Merck Research Labs
  • Dr. Steven Paul, President and Chief Executive Officer, Voyager Therapeutics

Moderator:
Dr. Steve Uden, Co-Founder, Rallybio

11-05 AM -11-35 AM Networking Break
11-35 AM – 12-25 PM Panel Discussion: Oncology

Panelists:

  • Dr. Bruce Chabner, Director of Clinical Research, Mass General Hospital Cancer Center/Harvard Medical School
  • Dr. Kurt Stoeckli, President and Chief Scientific Officer, Glenmark Pharmaceuticals
  • Dr. Philip Rowlands, Head of the Oncology Therapeutic Area Unit, Takeda Pharmaceuticals
  • Dr. Victoria Richon, President & CEO, Ribon Therapeutics
  • Dr. Rakesh Jain, Director, E.L. Steele Laboratory of Tumor Biology,  Mass General Hospital Cancer Center/HMS

Moderator:
Dr. Raju Kucherlapati, Professor of Genetics, Harvard Medical School

12-25 PM – 1-00 PM Fireside Chat:

  • Dr. Ansbert Gadicke, Founder & Managing Director, MPM Capital
  • Dr. Stelios Papadopoulos, Chairman, Biogen
  • Dr. Tsutomu Une, Senior Corporate Advisor, GCA Corporation

Moderator: 
Dr. William Chin, Professor of Medicine, Emeritus, Harvard Medical School

1-00 PM – 2-40 PM Luncheon Panel Discussion: Technology Platforms

Panelists:

  • Chris Benko, Co-Founder & CEO, Koneksa Health
  • Colin Hill, Chairman & CEO, GNS Healthcare
  • Dr. Peter Mueller, Chairman, BioXcel Therapeutics
  • Dr. Shahram Ebadollahi, Vice President, Innovations & Chief Scientific Officer, IBM Watson Health Group, IBM
  • Dr. Vijay Chandru, Chairman, Strand Life Sciences

Moderator:
Dr. Ajay Dhankhar, Senior Partner, McKinsey and Company

2-40 PM – 3-15 PM Networking & Tea Break
3-15 PM – 3-35 PM BioPharma: An Extraordinary Disruption

Dr. Ajay Dhankhar, Senior Partner, McKinsey and Company
Sastry Chilukuri, Partner, McKinsey and Company

3-35 PM – 4-30 PM Panel Discussion: Drug Discovery and Development

Panelists:

  • Dr. Andrew Plump, Chief Medical & Scientific Officer, Takeda Pharmaceuticals
  • Dr. Mathai Mammen, Global Head of R&D, Janssen Pharmaceutical- Johnson & Johnson
  • Dr. Michael Ehlers, Executive Vice President and Head of Research & Development, Biogen

Moderator:
Dr. Martin Mackay, Co-Founder and CEO, Rallybio

4-30 PM – 5-05 PM Fireside Chat:

  • Dr. George Daley, Dean, Harvard Medical School
  • Dr. Susan Hockfield, President Emerita & Professor of Neuroscience, Massachusetts Institute of Technology (MIT)

Moderator:
Dr Andrew Plump, Chief Medical and Scientific Officer, Takeda Pharmaceuticals

5-05 PM – 5-10 PM Closing Remarks
5-10 PM – 6-30 PM Cocktails & Networking Reception

*Luncheon Panel Discussion: Lunch will be served at the table at 12:50 PM. Panel will start at 1:40 PM

* Speaker and Timings subject to change

Some of the Speakers and Participants


Dr. Andrew Plump
Chief Medical & Scientific Officer
Takeda Pharmaceuticals

Dr. James Bradner
President
Novartis Institutes for BioMedical Research

Prof. Susan Hockfield
President Emerita
MIT

Dr. Mathai Mammen
Global Head of R&D
Janssen R&D

Dr. Stelios Papadopoulos
Chairman- Biogen
Chairman- Exelixis

Dr. Martin Mackay
Co-Founder
Rallybio

Dr. R.K. Vats*
Additional Secretary
Ministry of Health & Family Welfare

Dr. George Daley
Dean
Harvard Medical School

Sanat Chattopadhyay
President- Merck Manufacturing Division
Merck & Co.

Dr. Steven Paul
President & CEO
Voyager Therapeutics

Dr. Bruce Chabner
Director of Clinical Research
Mass General Hospital Cancer Center

Dr. Eswara Reddy*
Drugs Controller General of India
Ministry of Health & Family Welfare

Dr. William W. Chin
Professor of Medicine, Emeritus
Harvard Medical School

Dr. Alfred Sandrock
Executive Vice President & CMO
Biogen

Dr. Jonathan Epstein
Executive Vice Dean & CSO
Perelman School of Medicine, UPenn

Dr. Chas Bountra
Chief Scientist
Structural Genomics Consortium Oxford

Dr. Katherine Bowdish
Head
Sanofi Sunrise

Dr. Philip Rowlands
Head of the Oncology TAU
Takeda Pharmaceuticals

Dr. Sridaran Natesan 
Vice President- Strategic Initiatives
Sanofi

Jim Gilbert
Senior Partner
Flagship Pioneering

Dr. Jim Glasheen
Executive Vice Chancellor
UMass Medical School

Dr. Steve Hitchcock
Global Head of Research
Takeda Pharmaceuticals

Dr. Victoria Richon
President & CEO
Ribon Therapeutics

Dr. Michael Ehlers
Executive Vice President R&D
Biogen

Prof. Nirmal Kumar Ganguly
Former Director General
ICMR

Dr. Rakesh Jain
Prof. of Tumor Biology
MGH/Harvard Medical School

Dr. Daniel Jay
Dean- Sackler School
Tufts University

Dr. Michael Mendelsohn
Founder & Executive Chairman
Cardurion Pharmaceuticals

Dr. Christiana Bardon
Managing Director
MPM Capital

Dr. Tsutomu Une
Senior Corporate Advisor
GCA Corporation

Dr. Maurizio Fava
Associate Dean for Translational Research
Harvard Medical School

Dr. Peter Mueller
Chairman
BioXcel Therapeutics

Dr. Anthony Muslin
Head of Cardiovascular & Fibrosis Research
Sanofi

Brad Margus
Chief Executive Officer
Cerevance

Dr. Steve Uden
Co-Founder
Rallybio

Dr. Kurt Stoeckli
President & CSO
Glenmark Pharmaceuticals

Dr. Shahram Ebadollahi
Chief Science Officer
IBM Watson Health Group

Dr. Carl Goldfischer
Managing Director
Bay City Capital

Philippe Lopes-Fernandes 
Senior Vice-President
Merck KGaA, Darmstadt, Germany

Dr. Michael Cima
Associate Dean of Innovation
MIT School of Engineering

Benjamin Thorner
Head of Business Dev & Licensing
Merck Research Labs

Dr. Tal Zaks
Chief Medical Officer
Moderna Therapeutics

Dr. Mario Saltarelli
SVP- Early Dev & Neurology
Vertex Pharmaceuticals

Dr. Ole Isacson
Professor of Neurology
Harvard Medical School

Dr. Iman El-Hariry
Chief Medical Officer
ERYTECH

Dr. Raju Kucherlapati
Professor of Genetics
Harvard Medical School

Dr. Kimberly Wagner
President & COO
CiBO Technologies

Dr. Lex H.T. Van der Ploeg
Chief Scientific Officer
Rhythm Pharma

Dr. Christopher Wright
Chief Development Officer
Ironwood Pharmaceuticals

Dr. Iya Khalil
Co-Founder & Exe. Vice President
GNS Healthcare

Juan Harrison
VP, Head of Strategic Academic Alliances
Takeda Pharmaceuticals

Dr. Vijay Chandru
Chairman
Strand Life Sciences

Vikas Sinha
Managing Director
MPM Capital

Dr. David Goldstein
Director-Institute for Genomic Medicine
Columbia University Medical Center

Dr. Birgit Schoeberl
Global Head Modeling & Simulation
Novartis Institutes for BioMed Res.

Dr. Ajay Dhankhar
Senior Partner
McKinsey and Company

Dr. Markus Haeberlein
Head of Discovery
Alkermes

Dr. Ajay Nirula
Vice President-Immunology
Eli Lilly

Dr. Isabel Aznarez
Co-Founder & Head of Biology
Stoke Therapeutics

Dr. Harith Rajagopalan
Co-Founder & CEO
Fractyl

Dr. Christopher Locher
Co-Founder & CEO
Versatope Therapeutics

Colin Hill
Co- Founder & Chairman
GNS Healthcare

Dr. Thomas Schuetz
Co-founder & CEO
Compass Therapeutics

Constantine Chinoporos
Chief Business Officer
Boston Pharmaceuticals

Dr. Frank Bobe
Entrepreneur-in-Residence
Wyss Institute

Sanjiv Patel
President & CEO
Relay Therapeutics

Dr. Rhonda Kaufman
Director
Foresite Capital Management

Dr. Meeta Chatterjee
Head- Business Strategy, BD&L
Merck Research Laboratories

Vinay Ranade
Head of Biosimilars
Reliance Life Sciences

Dr. Robert Copeland
Co Founder & President
Accent Therapeutics

Winston Kung
Chief Operating Officer
PMV Pharma

Dr. Femida Gwadry-Sridhar
Founder & CEO
Pulse Infoframe

Dr. Barry Ticho
Chief Medical Officer
Stoke Therapeutics

Dr. Patrick Anquetil
Chief Executive Officer
Portal Instruments

John Ripple
Chief Executive Officer
Exonics Therapeutics

Dr. James Cassella
Chief Development Officer
Concert Pharmaceuticals

Chris Benko
Co-Founder & CEO
Koneksa Health

Dr. Stefan Scherer
Head Early Dev, Strategy & Innovation
Novartis

Dr. Michael Vasconcelles
Chief Medical Officer
Unum Therapeutics

Jeff Hackman
Chief Operating Officer
Novelion Therapeutics

Read Full Post »


36th Annual J.P. Morgan HEALTHCARE CONFERENCE January 8 – 11, 2018

Reporter: Aviva Lev-Ari, PhD, RN

 

Keynotes

Monday, January 8
healthcare key headshot graphic bill gates
Bill Gates
Co-Chair and Trustee of the
Bill & Melinda Gates Foundation
Tuesday, January 9
Jamie Dimon Headshot
Jamie Dimon
Chairman and Chief Executive Officer,
JPMorgan Chase & Co.
Wednesday, January 10
healthcare key headshot graphic Paul
Paul Begala
Political Analyst and Commentator
for CNN
healthcare key headshot graphic tucker
Tucker Carlson
Host of Tucker Carlson Tonight
and Founder of The Daily Caller
SOURCE

Read Full Post »


Economic Potential of a Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) versus a Cancer Drug in Clinical Trials: CAR-T as a Case in Point, developed by Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

Curator: Aviva Lev-Ari, PhD, RN

 

UPDATED on 1/23/2018

Two CARTs, Two Charts: Dissecting Returns From T-Cell Therapy M&A

Bruce Booth

1/22/2018 Celgene finalized its acquisition of Juno Therapeutics for $9B, only a few short months after Gilead bought Kite Pharma for $11.9B.

It’s also clear that public investors did quite well in these deals – unlike some outcomes, both private and public investors can only be happy with these deals. Kite’s IPO investors made over a whopping 10x, and Juno’s nearly a 3.6x (in 3 years, so still a very strong public market return). Even the follow-on financing participants made handsome returns: both Kite’s and Juno’s follow-on financings about 4-6 months prior to acquisition delivered a 2x return in a short period. What’s clear is that participating at any point only these price curves was a positive for investors. Obviously that doesn’t always happen, but great to see when it does.

A final takeaway is that there is “no one size fits all” for how to build business models that can work in biotech these days, even to get to similar product and patient outcomes. While Kite and Juno have remarkably similar products, similar platforms, and similar overall acquisition valuations, the stories were built quite differently when it comes to financing their growth.

https://www.forbes.com/sites/brucebooth/2018/01/23/two-carts-two-charts-dissecting-returns-from-t-cell-therapy-ma/#23f0b7a2459e

UPDATED on 10/18/2017

Kite Pharma, under Arie Belldegrun, CEO, acquired by Gilead for $11.9 billion, 8/2017.

Kite’s Yescarta™ (Axicabtagene Ciloleucel) Becomes First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy

— Manufacturing Success Rate of 99 Percent in ZUMA-1 Pivotal Trial with a Median 17 Day Turnaround Time —

CAR T therapy is a breakthrough in hematologic cancer treatment in which a patient’s own T cells are engineered to seek and destroy cancer cells. CAR T therapy is manufactured specifically for each individual patient.

“The FDA approval of Yescarta is a landmark for patients with relapsed or refractory large B-cell lymphoma. This approval would not have been possible without the courageous commitment of patients and clinicians, as well as the ongoing dedication of Kite’s employees,” said Arie Belldegrun, MD, FACS, Founder of Kite. “We must also recognize the FDA for their ability to embrace and support transformational new technologies that treat life-threatening illnesses. We believe this is only the beginning for CAR T therapies.”

“Today is an important day for patients with relapsed or refractory large B-cell lymphoma who have run out of options and have been waiting for new treatments that may help them in their fight against cancer,” said John Milligan, PhD, President and Chief Executive Officer of Gilead Sciences. “With the combined innovation, talent and drive of the Kite and Gilead teams, we will rapidly advance cell therapy research and aim to bring new options to patients with many other types of cancer.”

The list price of Yescarta in the United States is $373,000.

Yescarta has been granted Priority Medicines (PRIME) regulatory support for DLBCL in the European Union. A Marketing Authorization Application (MAA) for axicabtagene ciloleucel is currently under review with the European Medicines Agency (EMA) and potential approval is expected in the first half of 2018.

Yescarta (axicabtagene ciloleucel) Pivotal Trial Results

The approval of Yescarta is supported by data from the ZUMA-1 pivotal trial. In this study, 72 percent of patients treated with a single infusion of Yescarta (n=101) responded to therapy (overall response rate) including 51 percent of patients who had no detectable cancer remaining (complete remission; 95% CI: 41, 62). At a median follow-up of 7.9 months, patients who had achieved a complete remission had not reached the estimated median duration of response (95% CI: 8.1 months, not estimable [NE]).

In the study, 13 percent of patients experienced grade 3 or higher cytokine release syndrome (CRS) and 31 percent experienced neurologic toxicities. The most common (≥ 10%) Grade 3 or higher reactions include febrile neutropenia, fever, CRS, encephalopathy, infections-pathogen unspecified, hypotension, hypoxia and lung infections. Serious adverse reactions occurred in 52% of patients and included CRS, neurologic toxicity, prolonged cytopenias (including neutropenia, thrombocytopenia and anemia), and serious infections. Fatal cases of CRS and neurologic toxicity occurred. FDA approved Yescarta with a Risk Evaluation and Mitigation Strategy.

Yescarta Indication

Yescarta is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL), accounting for three out of every five cases. In the United States each year, there are approximately 7,500 patients with refractory DLBCL who are eligible for CAR T therapy. Historically, when treated with the current standard of care, patients with refractory large B-cell lymphoma had a median overall survival of approximately six months, with only seven percent attaining a complete response. Currently, patients with large B-cell lymphoma in second or later lines of therapy have poor outcomes and greater unmet need, since nearly half of them either do not respond or relapse shortly after transplant.

“With CAR T therapy, we are reengineering a patient’s own immune system to detect and kill cancer cells, and the results have been impressive,” said Frederick L. Locke, MD, ZUMA-1 Co-Lead Investigator and Vice Chair of the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center in Tampa, Florida. “Many of the patients that received CAR T therapy had already relapsed several times with traditional treatments such as chemotherapy or hematopoietic stem cell transplant. Now, thanks to this new therapy many patients are in remission for months.”

“This therapy is a new option for patients with relapsed or refractory large B-cell lymphoma who have run out of treatment options and face a dire prognosis,” said Louis J. DeGennaro, PhD, President and Chief Executive Officer of The Leukemia & Lymphoma Society (LLS). “Early on, LLS recognized the potential of CAR T therapy and we are proud to be part of making this historic approval possible.”

“Engineered cell therapies like Yescarta represent the potential for a changing treatment paradigm for cancer patients,” said David Chang, MD, PhD, Worldwide Head of Research and Development and Chief Medical Officer at Kite. “Together, Gilead and Kite will accelerate studies of CAR T therapy in multiple blood cancers and advance other cell therapy approaches for solid tumors, with the goal of helping patients with diverse cancers benefit from this new era of personalized cancer therapy.”

http://www.businesswire.com/news/home/20171018006639/en/Kite%E2%80%99s-Yescarta%E2%84%A2-Axicabtagene-Ciloleucel-CAR-Therapy-Approved

This article has the following structure:

  • ABOUT Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent)
  • ABOUT Gilead’s $12 billion buy of Kite Pharma
  • ABOUT  the Drug Development process and the COMMERCIALIZATION GENIUS of Arie Belldegrun – Interviewed by Globes
  • ABOUT the Perspective of Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) following the Gilead’s $12 billion buy of Kite Pharma – Interviewed by Globes
  • ABOUT the Economic significance of Kite Pharma Acquisition for the Venture Capital Investment in Biotech in Israel
  • Key Opinion Leader’s View: Aviva Lev-Ari, PhD, RN

 

  1. I agree with Prof. Zelig Eshhar that this Case in Point is “one more invention, or parts of an invention, came from an Israeli laboratory (at the Weizmann Institute in this case) and fell into foreign hands. It is another enormous missed opportunity in the field of biomedicine and ethical drugs.”
  2. I agree with Prof. Zelig Eshhar that this Case in Point should have been a TEVA commercialization effort. It is a regrettable reality that the development and the manufacturing will not benefit the State of Israel, home of the Weitzman Institute where the Patentable invention took place by Prof. Zelig Eshhar.
  3. It is to be acknowledged that for CAR-T – the process of treatment using the drug – personalized genetic engineering of each patient’s cells – a grafting process with no precedent in the pharmaceutical industry (Juno has related process) – is bringing to the Oncology arena a NOVEL treatment for hematological malignancies cancer patients
  4. I agree with Prof. Zelig Eshhar that the Barriers in the pharmaceutical industry are especially high. Developing ethical drugs is a process requiring huge amounts of time, patience, money, and failures. It is exactly, therefore, all need to acknowledge that the Drug Development process and the COMMERCIALIZATION GENIUS of Arie Belldegrun is inseparable from the breakthrough invention of Prof. Zelig Eshhar to develop the drug from the Lab bench to the FDA accelerated process of Drug approval.
  5. The Biotech industry in Israel needs to develop more MDs, PhDs with the level of training of Arie Belldegrun and with his entrepreneur acumen, keenness and depth of perception, discernmentdiscrimination especially in practical aspects of Translation Medicine, Clinical Research, Clinical Trial Design and abilities to engage in innovating the FDA processes.
  6. The Biotech industry in US needs to develop more MDs, PhDs with the level of training of Prof. Zelig Eshhar to carry the scientific gravitas and the creativity to become inventors of novel drugs.

 

ABOUT Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent)

Pioneers of Cancer Cell Therapy:  Turbocharging the Immune System to Battle Cancer Cells — Success in Hematological Cancers vs. Solid Tumors

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2016/08/19/pioneers-of-cancer-cell-therapy-turbocharging-the-immune-system-to-battle-cancer-cells-success-in-hematological-cancers-vs-solid-tumors/

 

ABOUT Gilead’s $12 billion buy of Kite Pharma

FDA has approved the world’s first CAR-T therapy, Novartis for Kymriah (tisagenlecleucel) and Gilead’s $12 billion buy of Kite Pharma, no approved drug and Canakinumab for Lung Cancer (may be?)

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2017/08/30/fda-has-approved-the-worlds-first-car-t-therapy-novartis-for-kymriah-tisagenlecleucel-and-gileads-12-billion-buy-of-kite-pharma-no-approved-drug-and-canakinumab-for-lung-cancer-may-be/

 

ABOUT  the Drug Development process and the COMMERCIALIZATION GENIUS of Arie Belldegrun – Interviewed by Globes

“Chemotherapy will become just a bad memory”

More energetic than ever, Arie Belldegrun talks to “Globes” about Kite Pharma’s remarkable journey and the future of cancer treatment.

http://www.globes.co.il/en/article-chemotherapy-will-become-just-a-bad-memory-1001206978

 

ABOUT the Perspective of Drug Invention (Prof. Zelig Eshhar, Weitzman Institute, registered the patent) following the Gilead’s $12 billion buy of Kite Pharma – Interviewed by Globes

Kite Pharma was a $12b missed opportunity for Israel – Interview with Professor Zelig Eshhar

Some Israeli media headlines depicted Kite as an Israeli exit. But it is a US company that does no business in Israel and has no employees here.

Professor Zelig Eshhar is the man who registered the patent on the cancer treatment drug developed by Kite Pharma, recently acquired by Gilead for $11.9 billion.

“Globes”: Do you believe that any party in Israel could have financed the product and brought it where it is today?

Eshhar: “On the one hand, yes. The level of investment in the product before it reached Nasdaq was something that an Israeli concern could certainly have financed. On the other hand, Kite Pharma founder Professor Arie Belldegrun, with his energy and connections, brought it to a completely different place (Eshhar previously tried to interest various concerns in Israel in financing the drug, but all of them told him that it was too early, or that the product was not effective enough, E.T.).

Was the development already in its final form in the 1980s?

“Almost. I went to the National Institutes of Health (NIH), where I met for the first time Professor Steven Rosenberg, who later became the first doctor to conduct clinical trials with the technology. Rosenberg heard about my technology, and offered me exceptional conditions. We set up a team there, and had the best of everything. I only wish I had it now.”

They say that Belldegrun didn’t want the product at first. Today, he’s devoting all his efforts to it.

“When Arie founded Cougar Biotechnology, which developed a drug for prostate cancer, and was eventually sold to Johnson & Johnson for $1 billion, I contacted him and offered him the technology, but he was busy with Cougar’s product, and maybe didn’t think that he had enough capital for such a production. Only after he sold Cougar did he get back to me with an offer to buy the rights to my patent. At that time (2009-2010), the technology was already arousing great interest, and there were negotiations with several large companies.” (from an April 2015 “Globes” interview with Eshhar, who was awarded the Israel Prize).

Israelis can be very provincial. In at least some of the media headlines, Kite Pharma was portrayed as a “huge Israeli exit,” and the impression was given that it was an Israeli company. The truth is very different. Kite Pharma is not an Israeli company; it is a 100% US company. It does no business in Israel; its nearly $12 billion exit has no significance whatsoever for the Israeli economy, and will contribute nothing to it: no jobs, and the tax contribution will be marginal, and certainly not on the scale of Mobileye, for example. Let me say it again: Kite Pharma does not have even one employee in Israel (and has no reason to employ anyone here), and certainly does not pay taxes in Israel. There are no Israelis on the company’s management team or board of directors. This is a US company for all intents and purposes. The word “Israel” appears exactly once in the company’s full documents – where registration of the company’s patents is concerned. The fact that every story about the company mentions the small holdings of several Israeli financial institutions in it is a bad joke. Everyone should remember that Israeli financial institutions are of course entitled to invest in any foreign share, such as Google, Amazon, Facebook, Apple Computers, and so forth. Kite Pharma is one of those foreign shares, and nothing more.

Of course, there is cause for pride in the fact that Eshhar, owner of the patent for Kite Pharma’s drug is “one of ours,” i.e. an Israeli researcher at the Weizmann Institute of Science. Another source of pride is Kite Pharma founder and CEO Arie Belldegrun, a graduate of the Hebrew University Medical School who did his post-doctorate at the Weizmann Institute, where he met Eshhar, and Kite Pharma later bought his patent for the cancer drug. Belldegrun was also a director at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) until recently, resigning at the peak of that company’s crisis. Beyond this Israeli connection, however, the Kite Pharma exit has no great significance for Israel. All it means is that one more invention, or parts of an invention, came from an Israeli laboratory (at the Weizmann Institute in this case) and fell into foreign hands. It is another enormous missed opportunity in the field of biomedicine and ethical drugs.

It is necessary to realize that while Belldegrun is indeed a big biomedical brain with many achievements in the field, he is a brain that has left Israel, and we all have to ask ourselves why he left, why Kite Pharma is not an Israeli company, and why its (as yet non-existent) product was not developed in Israel and will not be manufactured there. The headline in Israel for the Kite Pharma exit should ask why Israel lost out on it, even though the patent came from Israeli laboratories, albeit with US cooperation.

Belldegrun is likely to keep his experiences on the Teva board of directors to himself. Of all the directors in the company, what he has to say is the most interesting, but he is unlikely to divulge what happened there with the inflated deal with Allergan, and exactly what he said at the board of directors meeting that approved the deal that led Teva into its current major crisis. The Kite Pharma exit and his other exits only highlight the lost opportunity. Kite Pharma, still without a product and without approval for a product, was sold for $11.9 billion in cash. Teva yesterday hit another low point, with a market cap of $16 billion. It is simply inconceivable: a company with an enormous potential, but no product, is worth three quarters of a huge veteran company with at least dozens of products, including products in the ethical drug sector. Kite Pharma is actually one of the indirect reasons for Teva’s decline – for the fact that Teva, which could have been a hothouse for developments like Copaxone, chose a huge inflated gamble on the generics market – a gamble that is now jeopardizing Teva’s future and very existence.

It is true that developing drugs is a very long process, requires huge amounts of capital, and involves many failures, but Teva decided to neglect it, and when a major company like Teva neglects Israeli developments, there are enough competitors in the pharma industry ready to turn Israeli research into gold. Kite Pharma is one example of this research.

The Weizmann Institute is a fruitful source of biomedical research. According to previous estimates published in “Globes,” the Weizmann Institute gets NIS 1 billion each year in royalties on medical and other developments, amounting to half of its budget. Directly and indirectly, the Weizmann Institute, together with other universities in Israel, is responsible for tens of billions of pharmaceutical sales. Only a few billions of this, however, results from drugs developed in Israel, like Copaxone, and far less than that is also made in Israel. The reports by Yeda R&D Company Ltd., the technology transfer arm of the Weizmann Institute of Science, are top secret, and there is a good reason for that. Exposing them will only highlight the scale of the missed opportunities. Instead of these inventions providing a base for a major pharmaceutical industry here, the commercialization companies are benefiting only the inventors and the Weizmann Institute itself (that is certainly natural and legitimate, and they are entitled to it), even though the research infrastructure from which they sprung is Israeli know-how, as in the case of Eshhar.

Barriers in the pharmaceutical industry are especially high. Developing ethical drugs is a process requiring huge amounts of time, patience, money, and failures. When it succeeds, however, the profit is enormous – for the industry, the employees, and the state (provided that some tax is paid). For example, Pfizer’s peak sales of Lipitor, a very popular drug for reducing cholesterol and fat in the bloodstream, reached $11 billion, and its profit on the drug was $9 billion, before competition from a generic version began. In addition to money, a great deal of experience and marketing power is required, and that is the reason why most developments wind up in the hands of major companies like Pfizer, Merck, and others at some stage. After all these qualifying statements, everyone who celebrated Kite Pharma’s exit should weep over it – it is another part of the sale of Israeli know-how overseas for a mess of pottage. Instead of consolidating a splendid pharma industry here, Israel is selling the brains with their know-how to foreigners. More than anything else, Teva’s decline and the Kite Pharma exit epitomize this sad and dangerous trend.

Published by Globes [online], Israel Business News – www.globes-online.com – on August 30, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017

http://www.globes.co.il/en/article-kite-pharma-the-huge-exit-that-israel-missed-1001203173

 

ABOUT the Economic significance of Kite Pharma Acquisition for the Venture Capital Investment in Biotech in Israel

Israeli investors profit from $11.9b Kite acquisition

Pontifax fund and Israeli institutional investors will profit from the US personalized cancer drug company’s huge sale.  Part of the technology was developed at the Weizmann Institute

Pharmaceutical company Gilead Sciences Inc. has announced that it will acquire US company Kite Pharma Inc., developer of personalized cancer treatment drugs, at a company value of $11.9 billion. This is one of the biggest ever acquisitions of a company whose products have not yet been approved for marketing. The company value for the acquisition reflects a 29% premium on the market price.

Kite Pharma has developed a new method for genetically engineering immune system cells, so that they will make a focused attack on the malignant tumor. The company was founded in the US by Israeli-American Professor Arie Belldegrun, who already has two exits to his credit. He is also a former director at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) (whose current value is not much more than the value at which Kite Pharma, a company with no products approved for marketing yet, is being acquired).

A significant part of the technology on which the product is based was developed by Professor Zelig Eshhar of the Weizmann Institute of Science.

The main Israeli beneficiary of the acquisition is the Pontifax fund, which invested $3.8 million in Kite Pharma at an early stage, but which distributed Kite Pharma shares worth $120 million to its investors. Among the investors in Pontifax that received shares in Kite Pharma are Menorah Mivtachim Holdings Ltd. (TASE: MORA) (which also bought shares on the market, and whose stake in the company is now worth over $100 million), The Phoenix Holdings Ltd. (TASE: PHOE1;PHOE5), Altshuler Shaham Ltd.Meitav Dash Investments Ltd. (TASE:MTDS), Harel Insurance Investments and Financial Services Ltd. (TASE: HARL), and Mori Arkin.

Kite Pharma is waiting for marketing approval of its first product, following a successful trial on 100 patients on a very abbreviated track for innovative cancer products. The product was initially designed for treatment of blood cancer, but it is now hoped that its use can later be expanded to treatment of other types of cancer. Gilead is making a big gamble, first of all that the US Food and Drug Administration (FDA) will fulfill its commitment to approve the product, even though the development plan it devised, together with the company, was very short and limited. The second gamble involves the process of treatment using the drug – personalized genetic engineering of each patient’s cells – a grafting process with no precedent in the pharmaceutical industry.

Speaking about the talks to sell Kite, Prof. Arie Belldegrun told “Globes.” “We handled like in the IDF 669 unit. Nobody knew anything. Nobody heard anything. We held meetings in places where nobody would see us. And before we announced it only five employees knew about it.”

Published by Globes [online], Israel Business News – www.globes-online.com – on August 28, 2017

© Copyright of Globes Publisher Itonut (1983) Ltd. 2017

http://www.globes.co.il/en/article-israeli-investors-profit-from-119b-kite-acquisition-1001202841

 

Other related articles published in this Open Access Online Scientific Journal include the following: 

Curators: Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN

  • Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2) – on Amazon since 5/18/2017

http://www.amazon.com/dp/B071VQ6YYK

Read Full Post »


LIVE HubWeek – Harvard, MIT, MGH, Boston multiple locations, 10/10 – 10/15, 2017

Reporter: Aviva Lev-Ari, PhD, RN

 

I attended several events on THU, October 12, 2017

DEEP DIVE: The AI Revolution in Medicine

9AM — 11:30AM Faneuil Hall

Panelists:

Jayashree Kalpathy-Cramer, PhD, co-director of the Quantitative Tumor Imaging at Martinos (QTIM) Lab at the A.A. Martinos Center for Biomedical Imaging at MGH

Tina Kapur, PhD, executive director of Image Guided Therapy, Department of Radiology, BWH

Katherine P. Andriole, PhD, FSIIM, director of Research Strategy and Operations, MGH and BWH Center for Clinical Data Science

Dina Katabi, PhD, Andrew & Erna Viterbi Professor of EE and CS at MIT, director of MIT Center for Wireless Networks and Mobile Computing

10:30 – 11:00AM: Generating data and other AI challenges

Highlights

  • Dina Katabi, PhD – presented 21st Century technologies under development at MIT
  • Katherine P. Andriole, PhD described innovations in EMR

Voices of Oncology Discovery – Presented by HMS Executive Education

Red Dome, 1:30-3PM

  • Thomas Lynch Jr., MD, Executive VP, CSO, BMS
  • Alice Shaw, MD, PhD, Paula O’Keeffe Endowed Chair of Thoracis Oncology, MGH, Associate Professor of Medicine, HMS
  • Arlene Sharpe, PhD, George Fabyan Prof. of Comparative Pathology, Co-Director Evergrande Center for Immunologic Disease, HMS
  • Linnea Olson, Artist, blogger, advocate and long-term cancer survivor
  • Stanley Y Shaw, MD, PhD, Associate Dean for Executive Education, HMS

Highlights

  • Success reported with targeted therapies, biomarkers facilitate Clinical Trial design provide benefits for translation to approval of therapies
  • Biomarkers enable to achieve enriched population in Clinical Trials
  • Genomics vs Tissue Agnostics – FDA approved a drug based on genomics ALONE
  • FDA – has a new directive requiring feedback from Patients
  • KRAS Mutation – no targeted therapy in existance yet
  • Targeted therapies are available for: EDFR, PD-L!, PD-L2, ALK
  • Price of Durg and Value to Patients: Impact on Big Pharma
  • Combination drug therapy is KING
  • Data analytics, Urgency for response to drugs, clinical trials have accelerated path to approval if no alternative on the market

VOICE of the Cancer survival patient:

  1. Don’t give up
  2. Patient must have a seat at the Table
  3. Cancer as chronic disease while a search for cure continues

The Personalized Cell Therapy Challenge: A Race against Time

Green Dome, 4:00PM – 5PM

Udit Batra, Dr. Shashi Murthy, David Williams, Bruce Levine, Goeff Hodge

 

Healthy Brain, Enlightened Brain

Faneuil Hall, 5;30PM – 7PM

Deepak Chopra, MD and Dr. Rudy Tanzi, Reverend Liz Walker

Highlights

  • Importance of Sleep

Health Buzz: Why How Much You Sleep Could Affect Your Risk for Alzheimer’s Disease

  • Importance od De-Stress Methods
  • Nutrition and Microbiome
  • Early detection of AD – 20 years before onset of symptomes

Book signing:

MGH- Institute for Brain Health

Jonathan Rosand, MD
Dr. Jonathan Rosand is a Co-Director and Co-Founder of the Mass General Institute for Brain Health, Professor of Neurology at Harvard, the J. P. Kistler Chair in Neurology, and Neurologist at Massachusetts General Hospital where he is Chief of the Division of Neurocritical Care and Emergency Neurology. A clinician-scientist with expertise in prevention of cerebrovascular diseases and preservation of brain function following stroke and brain injury, he brings the most advanced techniques of personalized medicine to his practice. In his laboratory within the Mass General Center for Human Genetic Research, Dr. Rosand directs a world-class research program in genetics that continues to discover new genes that influence susceptibility to and recovery from stroke.

Rudolph Tanzi, PhD
Dr. Rudy Tanzi is a Co-Director and Co-Founder of the Mass General Institute for Brain Health, Professor of Neurology and holder of the Joseph P. and Rose F. Kennedy Endowed Chair in Neurology and Mental Retardation at Harvard University, Vice-Chair of Neurology (Research) at MGH and Co-Chair of the Mass General Research Council. He received his Ph.D. in Neurobiology from Harvard University. The four new AD candidates discovered by the Alzheimer’s Genome Project, headed by Tanzi, were named as one of the ten top medical breakthroughs of 2008 by Time magazine. He has received the two highest awards in the field of AD research: The Metropolitan Life Award for Biomedical Research and the Potamkin Prize. Dr. Tanzi has co-authored over 450 research publications, and in 2012, co-authored the New York Times Best Selling book, “Super Brain”.

 

GO TO

https://hubweek.swoogo.com/tickets/begin?package_id=3184

Selection Price
The HUB Pass (FREE) $0.00
Designing Biology: New Paradigms for Collaboration
Oct 10, 2017, 10:30 AM – 12:15 PM
$0.00
How the Hub is Steering the Digital Health Revolution
Oct 10, 2017, 4:30 PM – 7:00 PM
$0.00
Total $0.00
Continue 
If you would like to register for more events, please select them below. If you have selected all the events that you would like to attend, please click “Continue” (You can always modify your schedule after you finish registering)

Choose your events:

Name Date & Time More Info
Leveraging Sustainable Design to Achieve Social Equity

Sold Out
Tuesday, October 10, 2017, 8:00 AM – 10:00 AM
The Organ Generation

Sold Out
Tuesday, October 10, 2017, 8:30 AM – 10:00 AM
Creating Connected Communities with Design Thinking–Ideation

Sold Out
Tuesday, October 10, 2017, 9:00 AM – 12:00 PM
Boston Landing Development Presentation Tuesday, October 10, 2017, 10:00 AM – 11:00 AM
Maximize Innovation with Universal Design Tuesday, October 10, 2017, 10:00 AM – 12:00 PM
Mobile @Scale Tuesday, October 10, 2017, 10:00 AM – 5:00 PM
Designing Biology: New Paradigms for Collaboration Tuesday, October 10, 2017, 10:30 AM – 12:15 PM
Fitness Class at Athlete’s Park Tuesday, October 10, 2017, 11:00 AM – 12:00 PM
Public Skate at the Warrior Ice Arena Tuesday, October 10, 2017, 12:00 PM – 3:00 PM
Women in Science Luncheon Tuesday, October 10, 2017, 12:00 PM – 2:00 PM
Programming the Future of AI: Ethics, Governance, and Justice

Sold Out
Tuesday, October 10, 2017, 12:00 PM – 1:00 PM
Salesforce Growth Camp Tuesday, October 10, 2017, 12:00 PM – 6:00 PM
Presentation Skills & Public Speaking Workshop

Sold Out
Tuesday, October 10, 2017, 12:45 PM – 2:15 PM
The Human Face of AI

Sold Out
Tuesday, October 10, 2017, 12:45 PM
Giza 3D: Visualizing the Pyramids

Sold Out
Tuesday, October 10, 2017, 1:00 PM – 2:00 PM
Ancient DNA: Mediterranean Pathogens and Mobility Tuesday, October 10, 2017, 2:00 PM – 5:00 PM
Building a Startup in Boston

Sold Out
Tuesday, October 10, 2017, 2:30 PM – 3:15 PM
The Art of Storytelling

Sold Out
Tuesday, October 10, 2017, 2:45 PM – 4:15 PM
Innovation at Boston Health Care for the Homeless Tuesday, October 10, 2017, 3:00 PM – 4:30 PM
Breaking Into Biotech

Sold Out
Tuesday, October 10, 2017, 3:30 PM – 5:00 PM
How AI Makes Us More Human

Sold Out
Tuesday, October 10, 2017, 4:00 PM – 5:00 PM
“Walk A Mile” Poverty Simulation Tuesday, October 10, 2017, 4:00 PM – 6:30 PM
How the Hub is Steering the Digital Health Revolution Tuesday, October 10, 2017, 4:30 PM – 7:00 PM
How To Connect With Anyone Tuesday, October 10, 2017, 4:45 PM – 6:15 PM
The Future of Robotics

Sold Out
Tuesday, October 10, 2017, 5:00 PM – 6:00 PM
Aging & Caregiving Digital Health Reverse Pitches Tuesday, October 10, 2017, 5:00 PM – 8:00 PM
The Neuroscience Behind Consumer Decision-Making Tuesday, October 10, 2017, 5:00 PM – 6:00 PM
Reducing & Managing Stress: Walking the Labyrinth Tuesday, October 10, 2017, 5:30 PM – 6:30 PM
Diversity in Business: How to Bring Meaningful Change Tuesday, October 10, 2017, 5:30 PM – 7:30 PM
Innovation in the Regional Food System Tuesday, October 10, 2017, 6:00 PM – 8:00 PM
When the Best Idea Fails Tuesday, October 10, 2017, 6:00 PM – 7:30 PM
Activating Purpose in the Workplace Tuesday, October 10, 2017, 6:00 PM – 8:00 PM
Venture Café Kendall Connect Tuesday, October 10, 2017, 6:00 PM – 7:30 PM
Open House at The Engine Tuesday, October 10, 2017, 6:00 PM
HUBweek Roxbury Innovation Showcase Tuesday, October 10, 2017, 6:00 PM – 9:00 PM
Hiring & Reskilling for the Future Tuesday, October 10, 2017, 6:30 PM – 8:30 PM
Create, Engage & Change: Urbano Project Open Studio Tuesday, October 10, 2017, 6:30 PM – 9:30 PM
Are You Truly Connected? Tuesday, October 10, 2017, 6:30 PM – 9:00 PM
The Changing Boston Designscape Tuesday, October 10, 2017, 6:30 PM – 8:30 PM
How To Be A Successful Networker Tuesday, October 10, 2017, 6:45 PM – 8:15 PM
The Science of 3D Knitting Tuesday, October 10, 2017, 7:45 PM
Finding Heaven Under Our Feet Tuesday, October 10, 2017, 8:00 PM – 9:45 PM
Behind The Scenes Of Successful Entrepreneurs Wednesday, October 11, 2017, 8:00 AM – 10:00 AM
Tour: Design Biennial Boston Wednesday, October 11, 2017, 8:30 AM – 9:30 AM
Engineering + Entrepreneurship: Innovation in Healthcare Wednesday, October 11, 2017, 9:00 AM – 3:00 PM
The Silk Road: Taking Breakthroughs Global Wednesday, October 11, 2017, 9:00 AM
Cancer Disparities + Diversity in Life Sciences Wednesday, October 11, 2017, 10:00 AM – 11:00 AM
MIT Public Art and Architecture Tour (Morning)

Sold Out
Wednesday, October 11, 2017, 10:00 AM – 11:00 AM
War on Cancer 3.0 Wednesday, October 11, 2017, 11:00 AM – 12:00 PM
Kendall Square: Innovation Playground Wednesday, October 11, 2017, 12:00 PM
How to Attract Global Entrepreneurs to Boston Wednesday, October 11, 2017, 12:00 PM – 1:00 PM
AAUW Work Smart in Boston Salary Negotiation Workshop I Wednesday, October 11, 2017, 12:00 PM – 2:00 PM
Free Yoga & Meditation Class Wednesday, October 11, 2017, 12:15 PM – 2:00 PM
Creating Connected Communities with Design Thinking–Rapid Prototyping Wednesday, October 11, 2017, 1:00 PM – 4:00 PM
Bully Boy Distillery Tour Wednesday, October 11, 2017, 1:30 PM – 3:30 PM
Art of Talking Science Competition: Rise of the Machines Wednesday, October 11, 2017, 2:00 PM – 4:00 PM
MIT Public Art and Architecture Tour (Afternoon)

Sold Out
Wednesday, October 11, 2017, 2:00 PM – 3:00 PM
The Harvard Yard Archaeology Project Wednesday, October 11, 2017, 2:30 PM – 3:30 PM
Inside the Brigham: Innovation in Action Wednesday, October 11, 2017, 3:00 PM – 6:00 PM
Marine Science Boston Harbor Cruise

Sold Out
Wednesday, October 11, 2017, 3:00 PM – 5:00 PM
5th Annual BUILD Entrepreneur Games Wednesday, October 11, 2017, 3:00 PM – 7:30 PM
Healthcare Redesign Collaborative Wednesday, October 11, 2017, 3:30 PM – 6:00 PM
Ramp-Up E-commerce Conversions Wednesday, October 11, 2017, 3:45 PM – 5:45 PM
Healthcare and the Experience Economy Wednesday, October 11, 2017, 4:00 PM – 6:30 PM
Harvard Innovation Labs Startup Showcase and Stories Wednesday, October 11, 2017, 4:00 PM – 6:00 PM
Green Innovation Industry Night Wednesday, October 11, 2017, 4:00 PM – 8:00 PM
Decoding the Dynaymic Cyber Threat Landscape Wednesday, October 11, 2017, 4:00 PM – 6:30 PM
IoT for Good: Connected, Inclusive, Smart Cities

Sold Out
Wednesday, October 11, 2017, 4:30 PM – 6:30 PM
Rare Rights. Common Cause. Wednesday, October 11, 2017, 4:45 PM
Dell PolicyHack Wednesday, October 11, 2017, 5:00 PM – 9:00 PM
The Female Entrepreneur’s Experience in Boston Wednesday, October 11, 2017, 5:00 PM – 7:00 PM
Love the Problem Showcase! Innovation That Solves Wednesday, October 11, 2017, 5:30 PM – 7:30 PM
AAUW Work Smart in Boston Salary Negotiation Workshop II Wednesday, October 11, 2017, 5:30 PM – 7:30 PM
Fall Café Night: District Hall’s 4th Birthday Party Wednesday, October 11, 2017, 5:30 PM – 9:00 PM
Geometry As Public Art: The Immigrant Experience Wednesday, October 11, 2017, 5:30 PM – 6:30 PM
Artificial Intelligence (and More) in Healthcare Wednesday, October 11, 2017, 5:30 PM – 7:30 PM
Celebration of Student Entrepreneurship in Boston Wednesday, October 11, 2017, 6:00 PM – 8:00 PM
Two Lenses: Communicating Science Wednesday, October 11, 2017, 6:00 PM – 8:00 PM
Innovation, the New Foundation of Urban Living Wednesday, October 11, 2017, 6:00 PM – 7:30 PM
Twilight: Exploring the Unconscious Mind Wednesday, October 11, 2017, 6:00 PM – 7:30 PM
The City Talks: STEAM Wednesday, October 11, 2017, 6:00 PM – 7:00 PM
Fact/Fiction: Driving Truth into Policy Debates Wednesday, October 11, 2017, 6:00 PM – 7:30 PM
Civic Series presents: Breaking Through Gridlock Wednesday, October 11, 2017, 6:00 PM – 8:30 PM
Runnin’: A circle of friends. An American epidemic. Wednesday, October 11, 2017, 6:30 PM – 8:00 PM
GlobeDocs: Opening Night Film–Bending the Arc Wednesday, October 11, 2017, 7:00 PM – 9:00 PM
GlobeDocs: Opening Night Film–Bending the Arc + Reception Wednesday, October 11, 2017, 7:00 PM – 11:00 PM
Environmental Film Festival: Happening – A Clean Energy Revolution Wednesday, October 11, 2017, 7:00 PM – 9:00 PM
The City Talks: Art and Medicine Wednesday, October 11, 2017, 7:30 PM – 8:30 PM
Innovation Women Pop-up (Thursday) Thursday, October 12, 2017, 8:00 AM
Deep Dive: The A.I. Revolution in Medicine Thursday, October 12, 2017, 9:00 AM – 12:00 PM
What it Means to be Part of a Movement Thursday, October 12, 2017, 11:00 AM – 12:00 PM
Exploration Phase I (Thursday) Thursday, October 12, 2017, 12:00 PM – 1:00 PM
Swiss-Made: Fulldome Immersive I (Thursday) Thursday, October 12, 2017, 1:00 PM – 1:30 PM
Swiss-Made: Fulldome Immersive II (Thursday) Thursday, October 12, 2017, 1:30 PM – 2:00 PM
Made in USA: Fulldome Immersive I (Thursday) Thursday, October 12, 2017, 2:00 PM – 2:30 PM
Deep Dive: Voices of Oncology Thursday, October 12, 2017, 2:00 PM – 3:30 PM
Do We Trust Our Digital Economy? Thursday, October 12, 2017, 2:30 PM – 3:30 PM
Abstract Superconscious (Thursday) Thursday, October 12, 2017, 2:30 PM
SAT FEST 2017 (Thursday) Thursday, October 12, 2017, 3:00 PM – 3:45 PM
Uncharted Domain (Thursday) Thursday, October 12, 2017, 3:00 PM
Linked Threats: Climate Change and Social Inequality Thursday, October 12, 2017, 3:35 PM – 4:15 PM
Made in USA: Fulldome Immersive II (Thursday) Thursday, October 12, 2017, 3:45 PM – 4:45 PM
Social Justice and the New Food Activism Thursday, October 12, 2017, 4:00 PM – 5:30 PM
Investing in American Jobs Thursday, October 12, 2017, 4:15 PM – 5:00 PM
Fullscale Dome-ination (Thursday) Thursday, October 12, 2017, 4:30 PM – 5:00 PM
Future Forum: Thursday Night Session Thursday, October 12, 2017, 5:00 PM – 7:00 PM
Swiss-Made: Fulldome Immersive III (Thursday) Thursday, October 12, 2017, 5:00 PM – 5:30 PM
Swiss-Made: Fulldome Immersive IV (Thursday) Thursday, October 12, 2017, 5:30 PM – 6:00 PM
MIT IDE Inclusive Innovation Challenge Celebration Thursday, October 12, 2017, 6:00 PM – 7:30 PM
Immersion Artists Talk Series Thursday, October 12, 2017, 6:30 PM – 8:30 PM
LIVE Silent Disco Thursday, October 12, 2017, 7:00 PM – 10:00 PM
Exploration Phase II (Thursday) Thursday, October 12, 2017, 7:00 PM – 8:00 PM
Wasted! The Story of Food Waste Thursday, October 12, 2017, 7:00 PM – 9:00 PM
GlobeDocs: Unrest Thursday, October 12, 2017, 7:30 PM – 9:30 PM
Live: Disorder 3D–Digital Choreography (Thursday) Thursday, October 12, 2017, 8:00 PM – 8:30 PM
Live: Disorder 3D–Digital Choreography (Friday) Thursday, October 12, 2017, 8:45 PM – 9:15 PM
Live: Disorder 3D–Digital Choreography (Saturday) Thursday, October 12, 2017, 9:30 PM – 10:00 PM
Innovation Women Pop-up (Friday) Friday, October 13, 2017, 8:00 AM
Deep Dive: Climate Change Friday, October 13, 2017, 9:00 AM – 12:00 PM
Swiss-Made: Fulldome Immersive I (Friday) Friday, October 13, 2017, 9:00 AM – 9:30 AM
Disrupting Poaching Networks Before They Kill Friday, October 13, 2017, 9:15 AM – 10:00 AM
Swiss-Made: Fulldome Immersive II (Friday) Friday, October 13, 2017, 9:30 AM – 10:00 AM
Made in USA: Fulldome Immersive II (Friday) Friday, October 13, 2017, 10:00 AM – 10:45 AM
Around Us. On Us. Within Us. Friday, October 13, 2017, 10:30 AM – 11:15 AM
Abstract Superconscious (Friday) Friday, October 13, 2017, 10:45 AM
Housing the Workforce:Typology Technology & Tectonics Friday, October 13, 2017, 11:05 AM – 11:55 AM
Initiative: The Women Behind Digital Health Friday, October 13, 2017, 12:00 PM – 1:15 PM
Exploration Phase I (Friday) Friday, October 13, 2017, 12:00 PM – 1:00 PM
Deep Dive: Innovations in Opioid Treatment and Recovery Friday, October 13, 2017, 1:00 PM – 4:00 PM
Swiss-Made: Fulldome Immersive III (Friday) Friday, October 13, 2017, 1:00 PM – 1:30 PM
Swiss-Made: Fulldome Immersive IV (Friday) Friday, October 13, 2017, 1:30 PM – 2:00 PM
Made in USA: Fulldome Immersive I (Friday) Friday, October 13, 2017, 2:00 PM – 2:30 PM
Planetary Explorations (Friday) Friday, October 13, 2017, 2:30 PM – 3:00 PM
Leading for Creativity Friday, October 13, 2017, 3:50 PM – 4:30 PM
Stories Under the Stars (Friday) Friday, October 13, 2017, 4:00 PM
Friday Night Session: Saving As Many Lives As Penicillin

Sold Out
Friday, October 13, 2017, 5:00 PM – 7:00 PM
The Swiss Touch: Exploring Digital Utopia Friday, October 13, 2017, 5:00 PM – 7:00 PM
Beantown Throwdown Friday, October 13, 2017, 5:30 PM – 8:00 PM
Askwith Forum – Changes in Mind Friday, October 13, 2017, 5:30 PM – 7:00 PM
Coffee & Chocolate: Climate Change, Sustainability, and Gender Equity Friday, October 13, 2017, 6:00 PM – 8:30 PM
The Room Where It Happens: On the Agency of Interior Spaces (Keynote) Friday, October 13, 2017, 6:00 PM – 7:30 PM
Environmental Film Festival: Chasing Coral Friday, October 13, 2017, 6:30 PM – 9:00 PM
Unchained Brain Friday, October 13, 2017, 6:30 PM – 7:45 PM
Exploration Phase II (Friday) Friday, October 13, 2017, 7:00 PM – 8:00 PM
GlobeDocs: Human Flow Friday, October 13, 2017, 7:30 PM – 9:30 PM
On Point Live Friday, October 13, 2017, 7:30 PM – 9:00 PM
The Cypher Friday, October 13, 2017, 8:00 PM – 10:30 PM
SAT FEST 2017 (Friday) Friday, October 13, 2017, 8:45 PM – 9:30 PM
Fullscale Dome-ination (Friday) Friday, October 13, 2017, 9:30 PM – 10:00 PM
Planetary Explorations (Friday Night) Friday, October 13, 2017, 10:00 PM – 10:30 PM
Cosmic Meditation (Saturday) Saturday, October 14, 2017, 8:15 AM
The Room Where It Happens: On the Agency of Interior Spaces (Symposium) Saturday, October 14, 2017, 9:00 AM – 5:00 PM
Made in USA: Fulldome Immersive II (Saturday) Saturday, October 14, 2017, 9:30 AM – 10:15 AM
De-Stress Boston Saturday, October 14, 2017, 10:00 AM – 12:00 PM
Demo Day: Showcase Floor Saturday, October 14, 2017, 10:00 AM
Demo Day: Intro to Startups and Entrepreneurship in Boston Saturday, October 14, 2017, 10:00 AM – 10:50 AM
Intergalactic Yoga (Saturday) Saturday, October 14, 2017, 10:15 AM
Demo Day: Growing a Startup in Boston: Challenges and Advantages Saturday, October 14, 2017, 11:00 AM – 11:50 AM
Uncharted Domain (Saturday) Saturday, October 14, 2017, 11:30 AM
Demo Day: How to be an Ally in the Workplace Saturday, October 14, 2017, 12:00 PM – 12:50 PM
Exploration Phase I (Saturday) Saturday, October 14, 2017, 12:00 PM – 1:00 PM
GlobeDocs: Circle Up/Lenox Street Saturday, October 14, 2017, 12:00 PM – 2:00 PM
Demo Day: Founders Talking About Failure Saturday, October 14, 2017, 1:00 PM – 1:50 PM
Swiss-Made: Fulldome Immersive I (Saturday) Saturday, October 14, 2017, 1:00 PM – 1:30 PM
Swiss-Made: Fulldome Immersive II (Saturday) Saturday, October 14, 2017, 1:30 PM – 2:00 PM
Abstract Superconscious (Saturday) Saturday, October 14, 2017, 2:00 PM
Demo Day: An Introduction to Funding Types Saturday, October 14, 2017, 2:00 PM – 2:50 PM
Swiss-Made: Fulldome Immersive III (Saturday) Saturday, October 14, 2017, 2:30 PM – 3:00 PM
GlobeDocs: Anatomy of a Male Ballet Dancer Saturday, October 14, 2017, 2:30 PM – 4:30 PM
Swiss-Made: Fulldome Immersive IV (Saturday) Saturday, October 14, 2017, 3:00 PM – 3:30 PM
Making a Live Storytelling Show for a Planetarium Saturday, October 14, 2017, 3:45 PM
Stories Under the Stars (Saturday) Saturday, October 14, 2017, 4:30 PM
GlobeDocs: Gladesmen – The Last of the Sawgrass Cowboys Saturday, October 14, 2017, 5:00 PM – 7:00 PM
Krip-Hop Nation: The Crossroads Experience Saturday, October 14, 2017, 5:00 PM – 6:00 PM
Made in USA: Fulldome Immersive I (Saturday) Saturday, October 14, 2017, 5:15 PM – 5:45 PM
SAT FEST 2017 (Saturday) Saturday, October 14, 2017, 5:45 PM – 6:30 PM
Demo Day: Finale Saturday, October 14, 2017, 6:00 PM – 8:00 PM
Fullscale Dome-ination (Saturday) Saturday, October 14, 2017, 6:30 PM – 7:00 PM
Exploration Phase II (Saturday) Saturday, October 14, 2017, 7:00 PM – 8:00 PM
WGBH: First Look: Bill Nye – Science Guy Saturday, October 14, 2017, 7:00 PM – 9:00 PM
GlobeDocs: Jaha’s Promise Saturday, October 14, 2017, 7:30 PM – 9:30 PM
Pico Picante Saturday, October 14, 2017, 8:00 PM – 10:30 PM
Modulate Live–Dance Party Saturday, October 14, 2017, 9:15 PM – 10:45 PM
Intergalactic Yoga (Sunday) Sunday, October 15, 2017, 9:00 AM
Stories Under the Stars (Sunday) Sunday, October 15, 2017, 10:15 AM
Cosmic Meditation (Sunday) Sunday, October 15, 2017, 10:45 AM
Robot Block Party Sunday, October 15, 2017, 11:00 AM
GlobeDocs: Shorts Program–Changing Perspective Sunday, October 15, 2017, 11:30 AM – 1:30 PM
Green Up New England Challenge Sunday, October 15, 2017, 11:45 AM – 12:45 PM
Exploration Phase I (Sunday) Sunday, October 15, 2017, 12:00 PM – 1:00 PM
Butterfly Effect: A Study in Prototyping, Art and Sustainability Sunday, October 15, 2017, 12:00 PM – 1:00 PM
Design Museum: Digitally-Enabled Creativity Sunday, October 15, 2017, 1:00 PM – 2:15 PM
Abstract Superconscious (Sunday) Sunday, October 15, 2017, 1:00 PM
A New Wave of Public Art in the Boston Area Sunday, October 15, 2017, 1:00 PM – 2:15 PM
Made in USA: Fulldome Immersive I (Sunday) Sunday, October 15, 2017, 1:30 PM – 2:00 PM
Planetary Explorations (Saturday) Sunday, October 15, 2017, 2:00 PM – 2:30 PM
GlobeDocs: Hondros Sunday, October 15, 2017, 2:00 PM – 4:00 PM
Designing for Climate Change Sunday, October 15, 2017, 2:20 PM – 3:00 PM
Fullscale Dome-ination (Sunday) Sunday, October 15, 2017, 2:30 PM – 3:00 PM
Creative Placemaking – A View on Tactical Urbanism Sunday, October 15, 2017, 3:30 PM – 4:30 PM
Swiss-Made: Fulldome Immersive III (Sunday) Sunday, October 15, 2017, 3:30 PM – 4:00 PM
GlobeDocs: Quest Sunday, October 15, 2017, 4:30 PM – 6:30 PM
GlobeDocs: I Am Evidence Sunday, October 15, 2017, 4:30 PM – 6:30 PM
GlobeDocs: Closing Night Film–A Fine Line Sunday, October 15, 2017, 7:00 PM – 9:00 PM
WGBH: First Look: Frontline: Putin’s Revenge Sunday, October 15, 2017, 7:00 PM – 9:00 PM
GlobeDocs: Closing Night Film–A Fine Line + Reception Sunday, October 15, 2017, 7:00 PM – 11:00 PM
Immersion Party 3-Pack

 

 

 

Read Full Post »


Success of the life sciences industry in Massachusetts: Governor Charlie Baker – A new 5 year, $500 million investment

Reporter: Aviva Lev-Ari, PhD, RN

 

We are thrilled to share this exciting news with you. Earlier today, Governor Charlie Baker announced he will be filing legislation to establish the next phase of the life sciences initiative with a new 5 year, $500 million investment. As the original 10-year, $1 billion program expires next year, this action is critical to the continued success of the life sciences industry in Massachusetts, and to patients around the world who continue to seek new treatments and cures they need and deserve.

As noted by the Governor’s office, the focus of this next phase of the life science initiative will include strengthening investments in human capital to fortify the state’s skilled workforce pipeline, expanding opportunities for companies to access both private investment capital and dynamic public infrastructure resources, developing new scientific innovations that deliver higher outcome, affordable therapies to patients, and leading the convergence revolution in digital health, biopharma, medical devices and engineering.

Over the last nine years the life science initiative and the Massachusetts Life Sciences Center has cemented Massachusetts as the life sciences leader nationally and across the world. In Cambridge and Boston we have the best, most dense biotech cluster in the world. In Worcester, we have a cluster which can stand on its own as one of the biggest in the country. And in the northern and southern parts of the state, jobs in the life sciences are growing faster than anywhere else in the state. With a $147,000 average salary, $9 billion in total payroll, and an expected 11,600 new jobs over the next five years, the life sciences is a huge economic engine for this state. With today’s announcement, we know that companies will continue to come and expand in Massachusetts for years to come and make our economy grow. 

Most importantly, the continuation of the life sciences initiative ensures that patients across the world will continue to receive the breakthrough cures and treatments that are being developed every day in Massachusetts. 

Today’s an exciting day for Massachusetts. We’re thrilled to be part of it.

– Bob Coughlin

 

SOURCE
From:
MassBio <communications@massbio.ccsend.com> on behalf of MassBio <robert.coughlin@massbio.org>

Reply-To: <communications@massbio.org>

Date: Monday, June 19, 2017 at 1:06 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Breaking News: Gov. Baker Announces Next Phase of Life Sciences Initiative

Read Full Post »


VC Investment in BioTech MegaHubs and Top R&D Spenders among Big Pharma

Reporter: Aviva Lev-Ari, PhD, RN

UPDATED on 4/26/2017

The top 10 pharma R&D budgets in 2016

The Top 10 Pharma R&D Budgets in 2016

Read More:

SOURCE

http://www.fiercebiotech.com/special-report/top-10-pharma-r-d-budgets-2016?utm_medium=nl&utm_source=internal&mrkid=993697&mkt_tok=eyJpIjoiT1RSbE9ESTRNR1pqWTJFNCIsInQiOiJFcUx4MFhxSFVGbVZhUkRGdUdRMTJMUGxFSEkrR0VTMEdXbjRvZkxmdXM4em4wRkg5QXZIOWJJWTgwNHR1a1dVbTRIUFwvNWRIXC9ZTkF5dHlpUUZ4bG1lS2c2NkszQk9oeGtRczhLcnYyalRSZEFjOEl6U3dUY2VaakxUbDdkNGNwIn0%3D

Book traversal links for The top 10 pharma R&D budgets in 2016

 

 

 

Table SOURCE: Thomson Reuters abd ENDPOINTS

According to both sources:

  • $3.5 billion for Silicon Valley plus the Bay Area and
  • $2.8 billion for New England.

Broken down by city, $6.1 billion went to

  • Boston ($2.7 billion),
  • San Jose ($2.5 billion) and
  • San Francisco/Berkeley ($1 billion).
  • San Diego ($725 million),
  • New York ($454 million) and
  • the Great Lakes area ($412 million)

SOURCE

Where the money is: Biotech’s megahubs command VC’s billions by john carrollJune 30, 2016 10:41 AM EDT, Updated: November 17, 2016 07:32 PM

The top 15 spenders in the global drug R&D business: 2017

by john carroll

April 24, 2017 05:22 AM EDT, Updated: 05:27 AM

The top five in the business saw their collective spending jump by more than $5 billion, from 2015 to 2016, based on the annual numbers filed largely — though not entirely — with the SEC and gathered by Endpoints News. Two of those companies,

  • Roche and the new number 2, a hard charging
  • Merck, accounted for the lion’s share of the increase. (To be sure, some onetime non-R&D spending, such as Merck’s patent settlement with Bristol-Myers on Keytruda, figured in. But so did bread and butter spending.)
  • Gilead also saw a significant increase in research costs, with
  • Eli Lilly — now off course following two bad setbacks for solanezumab and baricitinib — and the ever aggressive
  • Celgene joining the action as they pressed the accelerator on new drug programs.

Curiously, the added spending coincided with a bad drop in new drug approvals in 2016. But they don’t correlate, and we’ve already seen that turnaround under way as regulators get busy with a brand new year — and soon a brand new FDA commissioner.

SOURCE

https://endpts.com/special/top-research-budgets-in-pharma-and-biotech/

Read Full Post »

Older Posts »